Insights into the activation mechanism of human estrogen-related receptor γ by environmental endocrine disruptors.


Journal

Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 10 12 2018
accepted: 02 05 2019
revised: 08 04 2019
pubmed: 28 5 2019
medline: 26 11 2019
entrez: 26 5 2019
Statut: ppublish

Résumé

The estrogen-related receptor γ (ERRγ, NR3B3) is a constitutively active nuclear receptor which has been proposed to act as a mediator of the low-dose effects of a number of environmental endocrine-disrupting chemicals (EDCs) such as the xenoestrogen bisphenol-A (BPA). To better characterize the ability of exogenous compounds to bind and activate ERRγ, we used a combination of cell-based, biochemical, structural and computational approaches. A purposely created stable cell line allowed for the determination of the EC50s for over 30 environmental ERRγ ligands, including previously unknown ones. Interestingly, affinity constants (Kds) of the most potent compounds measured by isothermal titration calorimetry were in the 50-500 nM range, in agreement with their receptor activation potencies. Crystallographic analysis of the interaction between the ERRγ ligand-binding domain (LBD) and compounds of the bisphenol, alkylphenol and naphthol families revealed a partially shared binding mode and minimal alterations of the receptor conformation upon ligand binding. Further biophysical characterizations coupled to molecular dynamics simulations suggested a mechanism through which ERRγ ligands would exhibit their agonistic properties by preserving the transcriptionally active form of the receptor while rigidifying some loop regions with associated functions. This unique mechanism contrasts with the classical one involving a ligand-induced repositioning and stabilization of the C-terminal activation helix H12.

Identifiants

pubmed: 31127318
doi: 10.1007/s00018-019-03129-x
pii: 10.1007/s00018-019-03129-x
doi:

Substances chimiques

Benzhydryl Compounds 0
ESRRG protein, human 0
Endocrine Disruptors 0
Ligands 0
Phenols 0
Receptors, Estrogen 0
Recombinant Proteins 0
bisphenol A MLT3645I99

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4769-4781

Subventions

Organisme : Plan Cancer Inserm
ID : CONTERREC C16007FS
Organisme : Agence Nationale de la Recherche
ID : 13-CESA-0012-04
Organisme : Agence Nationale de la Recherche
ID : 14-ACHN-0016

Références

Environ Health Perspect. 2014 Dec;122(12):1306-13
pubmed: 25260197
J Comput Chem. 2004 Jul 15;25(9):1157-74
pubmed: 15116359
Mitochondrion. 2011 Jul;11(4):544-52
pubmed: 21497207
Cell Metab. 2016 Mar 8;23(3):479-91
pubmed: 26777690
Acta Pharmacol Sin. 2014 Dec 15;36(1):88-101
pubmed: 25500867
Cancer Res. 2002 Nov 15;62(22):6510-8
pubmed: 12438245
EMBO J. 2009 Jan 7;28(1):34-47
pubmed: 19078967
Acta Pharmacol Sin. 2015 Jan;36(1):51-61
pubmed: 25500872
Protein Eng Des Sel. 2010 Nov;23(11):809-15
pubmed: 20817759
Cell Metab. 2011 Mar 2;13(3):283-93
pubmed: 21356518
Receptors Clin Investig. 2014;1(5):null
pubmed: 26005698
J Mol Endocrinol. 2015 Jun;54(3):289-303
pubmed: 25878060
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
Mol Endocrinol. 2008 Mar;22(3):570-84
pubmed: 18063693
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713
pubmed: 26574453
PLoS Comput Biol. 2013 Apr;9(4):e1003012
pubmed: 23637584
Diabetes. 2016 Oct;65(10):2835-48
pubmed: 27335230
J Biol Chem. 2011 Nov 4;286(44):38035-42
pubmed: 21911493
Cancer Res. 2011 Apr 1;71(7):2518-28
pubmed: 21339306
Sheng Li Xue Bao. 2016 Aug 25;68(4):435-54
pubmed: 27546504
Biochem Biophys Res Commun. 2008 Aug 29;373(3):408-13
pubmed: 18582436
Hum Mol Genet. 2011 Mar 15;20(6):1074-83
pubmed: 21177257
Mol Cell. 2002 Feb;9(2):303-13
pubmed: 11864604
Mol Cell Endocrinol. 2018 Nov 5;475:74-91
pubmed: 29481862
Mol Cell Biol. 2015 Apr;35(7):1281-98
pubmed: 25624346
Nat Rev Endocrinol. 2011 Aug 16;7(12):715-26
pubmed: 21844907
J Recept Signal Transduct Res. 2012 Apr;32(2):47-56
pubmed: 22268851
J Mol Endocrinol. 2003 Aug;31(1):47-60
pubmed: 12914524
J Steroid Biochem Mol Biol. 2011 Jan;123(1-2):1-7
pubmed: 20883782
J Biol Chem. 2012 Jun 22;287(26):21628-39
pubmed: 22549789
Curr Top Med Chem. 2006;6(3):203-15
pubmed: 16515477
Cell Metab. 2007 May;5(5):345-56
pubmed: 17488637
Environ Health Perspect. 2008 Jan;116(1):32-8
pubmed: 18197296
Mol Endocrinol. 2013 Jun;27(6):940-52
pubmed: 23584901
J Biochem. 2007 Oct;142(4):517-24
pubmed: 17761695
J Biol Chem. 2005 Jan 14;280(2):1625-33
pubmed: 15528208
J Biol Chem. 2004 Aug 6;279(32):33639-46
pubmed: 15161930
Nat Rev Cancer. 2013 Jan;13(1):27-36
pubmed: 23192231
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
J Biol Chem. 1994 Feb 11;269(6):4458-66
pubmed: 8308015
Front Endocrinol (Lausanne). 2018 Sep 11;9:525
pubmed: 30254608
Front Endocrinol (Lausanne). 2015 May 26;6:83
pubmed: 26074877
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8880-4
pubmed: 11447273
Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9548-53
pubmed: 16769902
Cell Metab. 2007 Jul;6(1):13-24
pubmed: 17618853
Trends Endocrinol Metab. 2017 Apr;28(4):261-272
pubmed: 28209382
FEBS J. 2014 May;281(10):2431-42
pubmed: 24684682
Toxicol Lett. 2006 Dec 1;167(2):95-105
pubmed: 17049190
Anal Biochem. 2005 Sep 1;344(1):8-15
pubmed: 16038868
J Steroid Biochem Mol Biol. 2018 Feb;176:16-22
pubmed: 28159674
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14930-5
pubmed: 22927406
Diabetologia. 2014 Dec;57(12):2576-85
pubmed: 25205222
J Mol Endocrinol. 2003 Dec;31(3):349-57
pubmed: 14664699
Cell. 2000 Dec 8;103(6):843-52
pubmed: 11136970
Mol Endocrinol. 2010 Feb;24(2):299-309
pubmed: 19965931
J Chem Phys. 2007 Jan 7;126(1):014101
pubmed: 17212484
Reprod Toxicol. 2013 Dec;42:132-55
pubmed: 23994667
Cell Mol Life Sci. 2010 Apr;67(8):1219-37
pubmed: 20063036
FASEB J. 2014 Jul;28(7):3124-33
pubmed: 24744145
J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):44-54
pubmed: 17964775
Annu Rev Med. 2015;66:271-80
pubmed: 25587652
Cancer Res. 2004 Jul 1;64(13):4670-6
pubmed: 15231680

Auteurs

Erwan Thouennon (E)

Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm, Univ Montpellier, ICM, Montpellier, France.

Vanessa Delfosse (V)

Centre de Biochimie Structurale (CBS), Inserm, CNRS, Univ Montpellier, Montpellier, France.

Rémy Bailly (R)

Centre de Biochimie Structurale (CBS), Inserm, CNRS, Univ Montpellier, Montpellier, France.

Pauline Blanc (P)

Centre de Biochimie Structurale (CBS), Inserm, CNRS, Univ Montpellier, Montpellier, France.

Abdelhay Boulahtouf (A)

Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm, Univ Montpellier, ICM, Montpellier, France.

Marina Grimaldi (M)

Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm, Univ Montpellier, ICM, Montpellier, France.

Alessandro Barducci (A)

Centre de Biochimie Structurale (CBS), Inserm, CNRS, Univ Montpellier, Montpellier, France.

William Bourguet (W)

Centre de Biochimie Structurale (CBS), Inserm, CNRS, Univ Montpellier, Montpellier, France. william.bourguet@cbs.cnrs.fr.

Patrick Balaguer (P)

Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm, Univ Montpellier, ICM, Montpellier, France. patrick.balaguer@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH